NEW YORK (360Dx) – OncoMark on Wednesday announced €2.1 million ($2.2 million) in funding to commercialize its breast cancer diagnostic test.

The Irish diagnostics firm plans to launch the test, called OncoMasTR, in 2018, it said. A biomarker-based prognostic test for early-stage breast cancer, OncoMasTR is aimed at reducing the number of patients who needlessly receive chemotherapy.